Top Stories
L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM
Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM
Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

Aurobindo Pharma arm gets exclusive rights for BioFactura monoclonal antibody ustekinumab biosimilar
Aurobindo Pharma Ltd., a prominent pharmaceutical company, announced on Friday, July 7, that CuraTeQ Biologics Private, a wholly-owned subsidiary, has inked an exclusive licencing deal with the US-based BioFactura to commercialise BFI-751, a potential biosimilar to Stelara.
Ustekinumab is a recombinant monoclonal antibody used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It acts by blocking the interleukins IL-12 and IL-23.
Ustekinumab had close to $10 billion in global medication sales in 2022, the business reported in an exchange filing, offering a sizable prospect with a good range of indications and wider use.
According to the terms of the agreement, CuraTeQ has been given the sole right to commercialise BFI-751 in the US, EU, UK, Canada, ANZ, and a few other semi-regulated and developing markets across the world. The product will be manufactured at CuraTeQ facilities in Hyderabad, India, and will also have global manufacturing rights, according to the business.
Source: Media reports
Related News

L&T Partners with PS Technology to Revolutionise Railways
6 mins read. August 2, 2024 at 12:45 PM

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr
4 mins read. August 2, 2024 at 12:41 PM

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr
4 mins read. August 2, 2024 at 12:36 PM

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr
4 mins read. August 2, 2024 at 12:33 PM
Download app
Access BlinkX
everywhere
across device
